Proteomic discoveries in dementia and kidney disease: Harnessing 135 million measurements and 30 years of follow-up
ABSTRACT
The NIH-funded Atherosclerosis Risk in Communities (ARIC) Study, which began in 1987, is a treasure trove of longitudinal, clinical data for biomarker discovery. In this webinar, Josef Coresh will discuss how his team and collaborators have mined that data by connecting ARIC’s rigorous epidemiologic cohorts with breakthrough proteomic quantification enabled by the SomaScan® Assay.
Using the SomaScan Assay, ~5,000 proteins were measured on frozen plasma from three visits conducted during 1990-1992 (n>10,000), 1993-1995 (N>12,000) and 2011-2013 (N>5,000). Following quality control verification of high precision, data were cleaned and shared with approximately 100 scientists working with ARIC data, who developed 64 approved manuscript proposals (3 published thus far, 13 forthcoming).
Methods for discovery, internal, and external validation were developed with success for chronic kidney disease and dementia. Discoveries highlighted specific prognostic target proteins (e.g. SVEP for dementia and TNFsR1 and LMAN2 for CKD) and pathways for each disease with Mendelian Randomization evidence of causation supporting some as useful targets for intervention.
Josef Coresh, M.D., Ph.D
Professor of Epidemiology, Medicine and Biostatistics
Dr. Joe Coresh is the George W. Comstock Professor of Epidemiology, Biostatistics and Medicine at The Johns Hopkins University Bloomberg School of Public Health*, where he leads the ARIC study – a cohort of 16,000 participants followed since 1987 – and co-leads the CKD Prognosis Consortium (CKD-PC), which includes over 80 cohorts and >10 million participants from 40+ countries.
Dr. Coresh’s research portfolio is diverse following the blood vessels from the heart to the kidney and the brain with grants of over $5M/year focused on big data and molecular studies. An international expert in kidney and cardiovascular disease epidemiology, Dr. Coresh has co-authored over 800 research articles cited over 100,000 times, was vice-chair of the 2002 NKF guideline whose definition of kidney disease is now used globally, and co-published the equations used for estimating kidney function globally.
Each year since 2014 Dr. Coresh has been recognized as being among the top 1% of researchers in Clinical Medicine globally (by article citations). Among other awards, he received the top scientific and patient impact awards of the United States National Kidney Foundation (NKF Eknoyan and Hume awards) and American Society of Nephrology (ASN Scribner award).
*Nothing contained herein shall be construed to imply any support or endorsement of SomaLogic, Inc. by The Johns Hopkins University.
More webinars
WebinarBoutique Webinar Aptamers with protein-like side chains as a versatile tool for high-content proteomics
Proteins, encoded in 20,000 genes in humans, do much of the work in biology. Measuring proteins, which change in response to various perturbations and represent targets for almost all drugs, offers insights about the health status of an organism. Since proteins operate in complex networks rather than in isolation, measuring multiple proteins simultaneously offers richer insights compared to single protein measurements.
WebinarUsing Proteomics To Advance Understanding of Alzheimer’s Disease
Limited understanding due to its complex pathophysiology and lack of definitive biomarkers currently constrains the diagnosis and treatment of Alzheimer’s disease (AD). But new research is uncovering dynamic brain changes during Alzheimer’s progression, offering potential therapeutic targets. This webinar explores how proteomics and systems biology can be integrated to elucidate AD pathology.
WebinarPredictive modeling and reliable biomarker discovery in clinical omics studies
High-content omic technologies coupled machine learning methods have transformed the biomarker discovery process. However, the translation of computational results into scalable clinical biomarkers remains challenging. A rate-limiting step is the rigorous selection of reliable biomarker candidates among a host of biological features. Drawing examples from real-world clinical omics studies, I will introduce Stabl, a general machine learning framework that identifies a sparse, reliable set of biomarkers by integrating noise injection and a data-driven signal-to-noise threshold into multivariable predictive modeling.